Marinna Madrid, Co-Founder, Cellino | Onyx Live | JPM 2026

Regenerative medicine could transform the lives of over 100 million patients in the US alone – but today, manufacturing a single personalised cell therapy costs up to $500,000 and takes weeks by hand.

With zero FDA-approved personalised iPSC therapies on the market, the vast majority of patients who could benefit from regenerative treatments still can’t access them.

Cellino is unlocking that potential with an AI-guided, autonomous biomanufacturing platform that uses laser physics, machine learning, and robotics to produce personalised stem cells at scale. Key milestones include:

• $125 million in total funding, including a $25 million ARPA-H award
• FDA Advanced Manufacturing Technology designation secured in May 2025
• First hospital-based iPSC foundry deployed at Mass General Brigham
• Targeting regenerative treatments for Parkinson’s, heart disease, diabetes, and spinal cord injury
• Partnership with Polyphron in January 2026 to advance scalable personalised tissue replacements

At JPM 2026, Onyx sat down with Co-Founder, Marinna Madrid, to find out more.

A special thanks to our Onyx Live sponsors:

HUMPHREYS LAW – a focused, full-service law firm advising clients in the technology and media sectors. https://humphreys.law/

Panacea – AI-powered FDA consultants. File your IND in half the time. https://withpanacea.com/